IRC
STOK icon

Investors Research Corp’s Stoke Therapeutics STOK Stock Holding History

Investors Research Corp’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-50
Closed -$417 – 1118
2023
Q1 		$417 Hold
50
– – ﹤0.01% 1070
2022
Q4 		$462 Hold
50
– – ﹤0.01% 1082
2022
Q3 		$1K Hold
50
– – ﹤0.01% 1058
2022
Q2 		$1K Hold
50
– – ﹤0.01% 1049
2022
Q1 		$1K Hold
50
– – ﹤0.01% 995
2021
Q4 		$1K Hold
50
– – ﹤0.01% 960
2021
Q3 		$1K Hold
50
– – ﹤0.01% 968
2021
Q2 		$2K Hold
50
– – ﹤0.01% 911
2021
Q1 		$2K Hold
50
– – ﹤0.01% 906
2020
Q4 		$3K Buy
50
+16
+47% +$733 ﹤0.01% 977
2020
Q3 		$1K Buy
+34
New +$971 ﹤0.01% 1060

Other funds holding STOK

ST
Skorpios Trust Limassol, Cyprus $53.2M AUM 90.96% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Investors Research Corp's STOK Position: Q2 2023 in Review

Investors Research Corp sold out of Stoke Therapeutics (STOK) in Q2 2023, closing a stake of 50 shares — an estimated $417 sold.

Investors Research Corp first reported a position in STOK in Q3 2020 and held it in 11 quarters. The position peaked at $3K in Q4 2020. 100 funds tracked by Wall St. Rank hold STOK as of Q2 2023.

  • Investors Research Corp reported no remaining Stoke Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Investors Research Corp sold 50 Stoke Therapeutics shares in Q2 2023, an estimated $417.
  • Investors Research Corp first reported a position in Stoke Therapeutics in Q3 2020 and held it in 11 quarters.
  • Investors Research Corp's Stoke Therapeutics position peaked at $3K in Q4 2020.
  • 100 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2023.

Based on Investors Research Corp's 13F filing for Q2 2023, filed 14 Aug 2023.